What does First Tracks Biotherapeutics, Inc. do?
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors;…
What is First Tracks Biotherapeutics, Inc.'s P/E and P/B ratio?
First Tracks Biotherapeutics, Inc. has a P/E ratio of -9.2 and a P/B ratio of 9.13.
What is First Tracks Biotherapeutics, Inc.'s debt-to-equity ratio?
First Tracks Biotherapeutics, Inc. has a debt-to-equity ratio of 0.03.
How much does First Tracks Biotherapeutics, Inc. owe compared with what it owns?
First Tracks Biotherapeutics, Inc. owes $0.08 for every $1 it owns (balance sheet Jun 2026), which is low.
What is First Tracks Biotherapeutics, Inc.'s Positivity rank?
First Tracks Biotherapeutics, Inc. is ranked #5,783 of 6,774 companies globally and #3,208 of 4,000 in United States on PositoAI, with a Positivity Score of 15,426.
Does First Tracks Biotherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for First Tracks Biotherapeutics, Inc..
Where can I read the latest news about First Tracks Biotherapeutics, Inc.?
Recent headlines about First Tracks Biotherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does First Tracks Biotherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of First Tracks Biotherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.